Cytokinetics, Incorporated (CYTK) News
Follow Cytokinetics, Incorporated (CYTK) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 38 public stories across 19 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Cytokinetics' Myqorzo Could Inflect Revenue Starting 2027, RBC Capital Markets Says
12:18 PM EST, 11/05/2026 (MT Newswires) -- Cytokinetics' (CYTK) Myqorzo could inflect revenue in 202
EQUITY | Nov 05, 2026, 05:18 PM UTC
M
Cytokinetics Q3 2026 Earnings Call Begins
Cytokinetics' quarterly earnings call has begun.
EQUITY | Nov 04, 2026, 09:27 PM UTC
M
Cytokinetics Reports Third-Quarter Revenue of $47.6 Million
EQUITY | Nov 04, 2026, 09:15 PM UTC
M
Cytokinetics Q3 Net Loss Narrows 38% to $190.07 Million
EQUITY | Nov 04, 2026, 09:02 PM UTC
L
Cytokinetics Reports Q3 Basic EPS in USD
EARNINGS | Nov 04, 2026, 09:01 PM UTC
M
Cytokinetics Reports Third-Quarter 2026 Financial Results
EQUITY | Nov 04, 2026, 09:00 PM UTC
M
Cytokinetics reports third-quarter loss of $1.37 per share
EQUITY | Nov 04, 2026, 09:00 PM UTC
M
Cytokinetics Wins Health Canada Approval for MYQORZO
Health Canada approved MYQORZO (aficamten) to treat adults with NYHA class II–III obstructive hypertrophic cardiomyopathy, Cytokinetics said. The company said this is its fifth approval, after approvals in the U.S., Chin
REGULATION | Oct 19, 2026, 11:35 AM UTC
L
Health Canada Approves Cytokinetics’ MYQORZO for Symptomatic oHCM
Health Canada issued a Notice of Compliance authorizing Cytokinetics’ aficamten treatment for adults with symptomatic obstructive hypertrophic cardiomyopathy.
REGULATION | Oct 19, 2026, 11:34 AM UTC
L
Health Canada approves Cytokinetics’ MYQORZO for obstructive HCM
Health Canada approved aficamten for adults with symptomatic obstructive hypertrophic cardiomyopathy.
REGULATION | Oct 19, 2026, 11:30 AM UTC
L
Cytokinetics presents additional ACACIA-HCM data
The company announced additional data from ACACIA-HCM presented at the HFSA Annual Scientific Meeting 2026.
EQUITY | Oct 12, 2026, 08:00 PM UTC
H
Cytokinetics Q2 2026 Earnings Call: Complete Transcript
On Thursday, Cytokinetics (NASDAQ: CYTK ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and tra
LIVE | Oct 12, 2026, 11:25 AM UTC
L
Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics, Incorporated NASDAQ:CYTK
NEWS | Sep 30, 2026, 11:34 AM UTC
L
Weekly Recap: MYQORZO US/Germany uptake and COMET/AMBER program updates
Cytokinetics, Incorporated (NASDAQ:CYTK) is rolling out MYQORZO for obstructive HCM with accelerating uptake (~2.5—3k patient starts, scripts up to ~1,500) while advancing omecamtiv and ulacamten trials, backed by partne
NEWS | Sep 28, 2026, 11:03 AM UTC
H
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
The biotech sector is heading into the third-quarter earnings season with a tug-of-war between higher interest rates and an unusually heavy pipeline of company-specific catalysts. The SPDR S&P Biotech ETF (NYSE: XBI ) is
LIVE | Sep 25, 2026, 08:19 PM UTC
L
CYTK: MYQORZO is set for broader HCM approval as commercial and pipeline strategies accelerate
ACACIA-HCM data has positioned MYQORZO for potential regulatory expansion to all HCM patients, with strong commercial momentum in OHCM and preparations for NHCM. The company is also advancing omecamtiv mecarbil in advanc
EQUITY | Sep 09, 2026, 08:59 PM UTC
L
CYTK: MYQORZO's strong launch and ACACIA-HCM data drive optimism for expanded HCM market leadership
ACACIA-HCM data positions MYQORZO for expanded HCM approval, with strong commercial momentum and rapid new-to-brand share growth. The NHCM market is now seen as a major opportunity, and preparations are underway for broa
EQUITY | Sep 09, 2026, 08:08 PM UTC
L
MYQORZO (aficamten) launched in major markets for oHCM
MYQORZO (aficamten) has launched in major markets for oHCM. The company says the launch is supported by clinical data and rapid commercial uptake, alongside pipeline and late-stage development for global expansion.
EQUITY | Sep 09, 2026, 07:12 PM UTC
L
CYTK - Cytokinetics to Participate in September Investor Conferences
CYTK - Cytokinetics to Participate in September Investor Conferences
EQUITY | Sep 02, 2026, 08:00 PM UTC
H
CYTK - Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the Euro
CYTK - Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
GEOPOLITICS | Aug 29, 2026, 02:37 PM UTC
L
Cytokinetics heart drug shows promise in trial, but analysts question modest benefits
Cytokinetics heart drug shows promise in trial, but analysts question modest benefits
EQUITY | Aug 28, 2026, 04:45 PM UTC
M
CYTK Aficamten data support FDA submission in non-obstructive HCM
CYTK says Aficamten showed significant, broad clinical benefit and safety in non-obstructive HCM, supporting an FDA submission.
REGULATION | Aug 28, 2026, 03:59 PM UTC
L
CYTK: Aficamten showed significant, broad, and durable benefits in non-obstructive HCM with manageable safety
CYTK: Aficamten showed significant, broad, and durable benefits in non-obstructive HCM with manageable safety
EQUITY | Aug 28, 2026, 01:56 PM UTC
M
Cytokinetics reports positive Phase 3 ACACIA-HCM results; plans FDA sNDA in Q4 2026
Cytokinetics says Phase 3 ACACIA-HCM results are positive and it plans to file an FDA sNDA in Q4 2026.
REGULATION | Aug 28, 2026, 01:34 PM UTC
M
CYTK plans FDA submission for aficamten in non-obstructive HCM
CYTK says aficamten showed robust efficacy and manageable safety in non-obstructive HCM, with an FDA submission planned.
REGULATION | Aug 28, 2026, 10:16 AM UTC
L
Cytokinetics eyes expanded use of heart drug after late-stage data
Cytokinetics is looking to expand use of its heart drug following promising late-stage data.
EQUITY | Aug 28, 2026, 09:50 AM UTC
L
Cytokinetics plans supplemental NDA submission for aficamten in Q4 2026
Cytokinetics plans to submit a supplemental NDA to the U.S. FDA for aficamten in Q4 2026.
REGULATION | Aug 28, 2026, 09:47 AM UTC
M
Cytokinetics cites positive ACACIA-HCM results at ESC 2026
Cytokinetics (CYTK) says it has positive ACACIA-HCM results, presented in a hot line session at the European Society of Cardiology (ESC) Congress 2026 and published in The New England Journal of Medicine.
GEOPOLITICS | Aug 28, 2026, 09:45 AM UTC
L
Cytokinetics (CYTK) schedules ESC Congress 2026 presentations
Cytokinetics (CYTK) announces upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, per TradeXchange Newsdesk.
GEOPOLITICS | Aug 20, 2026, 11:30 AM UTC
M
Cytokinetics announces inducement grants under Nasdaq Rule 5635(c)(4)
Cytokinetics (CYTK) announces inducement grants under Nasdaq Listing Rule 5635(c)(4), with no grant size, terms, or timing provided in the release text.
REGULATION | Aug 18, 2026, 08:00 PM UTC
H
Cytokinetics Price Target Raised To $110
Cytokinetics' Q2 exceeds expectations
EQUITY | Aug 07, 2026, 12:28 PM UTC
H
Cytokinetics Receives UK Marketing Authorization For MYQORZO For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult P
At the same time the National Institute for Health and Care Excellence (NICE) has issued guidance recommending aficamten for use in eligible adult patients in England and Wales. The guidance from NICE states that aficamt
EQUITY | Jul 30, 2026, 10:22 AM UTC
H
CYTK - Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstruc
CYTK - Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
EQUITY | Jul 30, 2026, 10:20 AM UTC
L
Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing
() -- Robert I Blum, Director, President & CEO, on July 13, 2026, sold 7,500 shares in Cytokinetics (CYTK) for $615,150. Following the Form 4 filing with the SEC, Blum has control over a total of 381,986 common shares of
GEOPOLITICS | Jul 14, 2026, 07:45 PM UTC
H
Cytokinetics price target lowered to $117 from $119 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm's price target on Cytokinetics to $117 from $119 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The
EQUITY | Jul 07, 2026, 11:30 AM UTC
L
Cytokinetics Insider Sold Shares Worth $1,287,000, According to a Recent SEC Filing
() -- Andrew Callos, Executive Vice President, Chief Commercial Officer, on July 01, 2026, sold 15,000 shares in Cytokinetics (CYTK) for $1,287,000. Following the Form 4 filing with the SEC, Callos has control over a tot
GEOPOLITICS | Jul 02, 2026, 09:22 PM UTC
M
CYTK: Mizuho Raises Target
Mizuho maintains outperform rating on Cytokinetics and raises price target to $118
EQUITY | Jun 24, 2026, 01:06 PM UTC
L
CYTK Mizuho raised the firm's price target on Cytokinetics to $118 from $100 and keeps an Outperform rating on the shares. The firm updated
CYTK Mizuho raised the firm's price target on Cytokinetics to $118 from $100 and keeps an Outperform rating on the shares. The firm updated the company's model following the Q1 report.
EQUITY | Jun 24, 2026, 12:48 PM UTC